Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra‐individual study

Background We know the efficacy of daylight phototherapy dynamic (DL‐PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effec...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 34; no. 8; pp. 1730 - 1735
Main Authors Assikar, S., Labrunie, A., Kerob, D., Couraud, A., Bédane, C.
Format Journal Article
LanguageEnglish
Published England 01.08.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background We know the efficacy of daylight phototherapy dynamic (DL‐PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs. Objectives The aim of this study is to assess the efficacy and the safety of DL‐PDT vs. PDT in blue light in the treatment of AKs. Methods This randomized, controlled, intra‐individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL‐PDT on one side and c‐PDT on the contralateral side. Primary endpoints for DL‐PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24. Results More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3‐month follow‐up was 19.6 (±6.0) for DL‐PDT and 20.0 (±6.9) for c‐PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL‐PDT was nearly painless than c‐PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001). Conclusions Daylight‐PDT seems as effective as c‐PDT with light blue and DL‐PDT is less painful. The response of DL‐PDT was sustainable until 6 months.
AbstractList We know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs.BACKGROUNDWe know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs.The aim of this study is to assess the efficacy and the safety of DL-PDT vs. PDT in blue light in the treatment of AKs.OBJECTIVESThe aim of this study is to assess the efficacy and the safety of DL-PDT vs. PDT in blue light in the treatment of AKs.This randomized, controlled, intra-individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL-PDT on one side and c-PDT on the contralateral side. Primary endpoints for DL-PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24.METHODSThis randomized, controlled, intra-individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL-PDT on one side and c-PDT on the contralateral side. Primary endpoints for DL-PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24.More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3-month follow-up was 19.6 (±6.0) for DL-PDT and 20.0 (±6.9) for c-PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001).RESULTSMore than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3-month follow-up was 19.6 (±6.0) for DL-PDT and 20.0 (±6.9) for c-PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001).Daylight-PDT seems as effective as c-PDT with light blue and DL-PDT is less painful. The response of DL-PDT was sustainable until 6 months.CONCLUSIONSDaylight-PDT seems as effective as c-PDT with light blue and DL-PDT is less painful. The response of DL-PDT was sustainable until 6 months.
We know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs. The aim of this study is to assess the efficacy and the safety of DL-PDT vs. PDT in blue light in the treatment of AKs. This randomized, controlled, intra-individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL-PDT on one side and c-PDT on the contralateral side. Primary endpoints for DL-PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24. More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3-month follow-up was 19.6 (±6.0) for DL-PDT and 20.0 (±6.9) for c-PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001). Daylight-PDT seems as effective as c-PDT with light blue and DL-PDT is less painful. The response of DL-PDT was sustainable until 6 months.
Background We know the efficacy of daylight phototherapy dynamic (DL‐PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs. Objectives The aim of this study is to assess the efficacy and the safety of DL‐PDT vs. PDT in blue light in the treatment of AKs. Methods This randomized, controlled, intra‐individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL‐PDT on one side and c‐PDT on the contralateral side. Primary endpoints for DL‐PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24. Results More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3‐month follow‐up was 19.6 (±6.0) for DL‐PDT and 20.0 (±6.9) for c‐PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL‐PDT was nearly painless than c‐PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001). Conclusions Daylight‐PDT seems as effective as c‐PDT with light blue and DL‐PDT is less painful. The response of DL‐PDT was sustainable until 6 months.
Author Couraud, A.
Labrunie, A.
Bédane, C.
Kerob, D.
Assikar, S.
Author_xml – sequence: 1
  givenname: S.
  orcidid: 0000-0003-1625-5203
  surname: Assikar
  fullname: Assikar, S.
  email: safae.assikar@chu-limoges.fr
  organization: CHU Dupuytren
– sequence: 2
  givenname: A.
  surname: Labrunie
  fullname: Labrunie, A.
  organization: CHU Dupuytren
– sequence: 3
  givenname: D.
  surname: Kerob
  fullname: Kerob, D.
  organization: Galderma International
– sequence: 4
  givenname: A.
  surname: Couraud
  fullname: Couraud, A.
  organization: CHU Dupuytren
– sequence: 5
  givenname: C.
  surname: Bédane
  fullname: Bédane, C.
  organization: CHU Dupuytren
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31955461$$D View this record in MEDLINE/PubMed
BookMark eNp9kbFu1TAUhi1URG8LAy-APNIhrR3HScyGWiigSizAGjn2MdfFsS-xkypMPAIPyNQnweEWBiTqxT4-3_8f6fxH6MAHDwg9peSU5nN2redTWpekfYA2tKrbgpGWHaANEWVdCMHFITqK8ZoQQilvH6FDRgXnVU036OeFXJz9vE14tw0p6MXLwSqctjDK3YJvbNriAdJ2cTg3fHAwT856mQCrEeSAbcQyYjAGVLIzrIUKfgafbPDS3WPbuwnwfrb1awun7JiGLMXBYJn9fNZ8yZIUoo0vsFyt0xicA41H6XUY7Lf8tPlT3n7_Yb22s9VTHhvTpJfH6KGRLsKTu_sYfXz96sP5m-Lq_eXb85dXhWIlbwtTaiIVlb2AilSSy1r0RIiqES0XjNSyNUaUhjfAm1ao2miu27KqmoYxxZueHaPne9_dGL5OEFM32KjAOekhTLErWVWyuqSEZ_TZHTr1A-huN9pBjkv3J5EMnOwBNYYYRzB_EUq6Ne0up939TjuzZ_-wyia5Lj7vw7r7FDfWwfJ_6-7dxae94hc8usLx
CitedBy_id crossref_primary_10_1016_j_dyepig_2024_112262
crossref_primary_10_3389_fchem_2021_691697
crossref_primary_10_1177_12034754241266177
crossref_primary_10_1016_j_ejcskn_2023_100004
crossref_primary_10_3390_cancers17061050
crossref_primary_10_1016_j_pdpdt_2021_102318
crossref_primary_10_3389_fonc_2024_1373263
crossref_primary_10_3390_cosmetics12010030
crossref_primary_10_62347_JOUT3260
crossref_primary_10_1016_j_rechem_2024_101715
crossref_primary_10_3390_ph15080985
crossref_primary_10_1016_j_pdpdt_2022_102752
crossref_primary_10_1016_j_pdpdt_2022_102783
crossref_primary_10_2147_CCID_S401206
Cites_doi 10.1111/jdv.13228
10.1016/j.ijsu.2011.09.004
10.1111/jdv.14613
10.1159/000366548
10.1117/1.JBO.20.5.058001
10.1159/000353775
10.1111/j.1365-2133.2011.10209.x
10.1111/j.1365-2133.2012.11200.x
10.2340/00015555-2345
10.1111/j.1600-0781.2011.00611.x
10.1111/j.1365-2133.2008.08450.x
10.1111/bjd.13138
10.1111/jdv.12974
10.1684/ejd.2016.2882
10.1111/jdv.13076
ContentType Journal Article
Copyright 2020 European Academy of Dermatology and Venereology
2020 European Academy of Dermatology and Venereology.
Copyright_xml – notice: 2020 European Academy of Dermatology and Venereology
– notice: 2020 European Academy of Dermatology and Venereology.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/jdv.16208
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-3083
EndPage 1735
ExternalDocumentID 31955461
10_1111_jdv_16208
JDV16208
Genre article
Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: CHU of Limoges
– fundername: Galderma
GroupedDBID ---
--K
.3N
.GA
.Y3
05W
0R~
10A
1B1
1OB
1OC
1~5
29L
31~
33P
36B
3SF
4.4
4G.
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AALRI
AAMNL
AANHP
AANLZ
AAONW
AAQFI
AAQXK
AASGY
AAXRX
AAXUO
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABQWH
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADZMN
AE3
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFTJW
AFWVQ
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
CO8
COF
CS3
CYRXZ
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
ESX
EX3
F00
F01
F04
F5P
FDB
FEDTE
FGOYB
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
NF~
NQ-
O66
O9-
OIG
OVD
OZT
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
R2-
RIG
RIWAO
RJQFR
ROL
RPZ
RX1
SAMSI
SEW
SUPJJ
TEORI
UB1
UHS
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
AAYXX
ACVFH
ADCNI
AEUPX
AEYWJ
AFPUW
AGHNM
AGQPQ
AGYGG
AIGII
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3258-f2d0ac1ab9e404a5a69b099479859306a8ff92f57e5789c6fd5d82447733c57b3
IEDL.DBID DR2
ISSN 0926-9959
1468-3083
IngestDate Fri Jul 11 16:12:49 EDT 2025
Mon Jul 21 05:59:28 EDT 2025
Tue Jul 01 04:12:05 EDT 2025
Thu Apr 24 22:54:19 EDT 2025
Wed Jan 22 16:32:41 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License 2020 European Academy of Dermatology and Venereology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3258-f2d0ac1ab9e404a5a69b099479859306a8ff92f57e5789c6fd5d82447733c57b3
Notes The tubes of Metvixia were supplied by Galderma. The rest of this study was funded by the CHU of Limoges.
None.
Conflict of interest
Funding source
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-1625-5203
PMID 31955461
PQID 2342362105
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_2342362105
pubmed_primary_31955461
crossref_primary_10_1111_jdv_16208
crossref_citationtrail_10_1111_jdv_16208
wiley_primary_10_1111_jdv_16208_JDV16208
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2020
2020-08-00
2020-Aug
20200801
PublicationDateYYYYMMDD 2020-08-01
PublicationDate_xml – month: 08
  year: 2020
  text: August 2020
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of the European Academy of Dermatology and Venereology
PublicationTitleAlternate J Eur Acad Dermatol Venereol
PublicationYear 2020
References 2015; 46
2015; 29
2017; 27
2015; 20
2013; 227
2016; 96
2013; 168
2014; 151
2008; 158
2014; 171
2011; 27
2018; 32
2011; 9
2011; 164
e_1_2_5_15_1
e_1_2_5_14_1
e_1_2_5_17_1
e_1_2_5_9_1
e_1_2_5_16_1
e_1_2_5_8_1
e_1_2_5_11_1
e_1_2_5_7_1
e_1_2_5_10_1
e_1_2_5_6_1
e_1_2_5_13_1
e_1_2_5_5_1
e_1_2_5_4_1
e_1_2_5_3_1
e_1_2_5_2_1
Fai D (e_1_2_5_12_1) 2014; 151
References_xml – volume: 171
  start-page: 1164
  year: 2014
  end-page: 1171
  article-title: Daylight PDT with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional PDT in actinic keratosis treatment: a randomised controlled trial
  publication-title: Br J Dermatol
– volume: 20
  start-page: 58001
  year: 2015
  article-title: Comparison of three light doses in the photodynamic treatment of actinic keratosis using mathematical modeling
  publication-title: J Biomed Opt
– volume: 9
  start-page: 672
  year: 2011
  end-page: 677
  article-title: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
  publication-title: Int J Surg
– volume: 32
  start-page: 595
  year: 2018
  end-page: 600
  article-title: Conventional vs. daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12‐month follow‐up results of a randomized, intra‐individual comparative analysis
  publication-title: J Eur Acad Dermatol Venereol
– volume: 96
  start-page: 712
  year: 2016
  end-page: 713
  article-title: Long‐term outcome of daylight photodynamic therapy with amino‐5‐laevulinate nanoemulsion vs. methyl‐5‐aminolaevulinate for actinic keratoses
  publication-title: Acta Derm Venereol
– volume: 158
  start-page: 740
  year: 2008
  end-page: 746
  article-title: Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single‐blinded study
  publication-title: Br J Dermatol
– volume: 29
  start-page: 2342
  year: 2015
  end-page: 2348
  article-title: Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator‐blinded, controlled, phase III study throughout Europe
  publication-title: J Eur Acad Dermatol Venereol
– volume: 151
  start-page: 154
  year: 2014
  end-page: 159
  article-title: Daylight photodynamic therapy with methyl aminolaevulinate in patients with actinic keratoses: a preliminary experience in southern Italy
  publication-title: G Ital Dermatol Venereol
– volume: 227
  start-page: 214
  year: 2013
  end-page: 225
  article-title: Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy
  publication-title: Dermatology
– volume: 29
  start-page: 1718
  year: 2015
  end-page: 1723
  article-title: Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus
  publication-title: J Eur Acad Dermatol Venereol
– volume: 27
  start-page: 280
  year: 2011
  end-page: 285
  article-title: Continuous ultra‐low‐intensity artificial daylight is not as effective as red LED light in photodynamic therapy of multiple actinic keratoses
  publication-title: Photodermatol Photoimmunol Photomed
– volume: 164
  start-page: 1083
  year: 2011
  end-page: 1090
  article-title: A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight‐mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp
  publication-title: Br J Dermatol
– volume: 46
  start-page: 122
  year: 2015
  end-page: 128
  article-title: Update on photodynamic treatment for actinic keratosis
  publication-title: Curr Probl Dermatol
– volume: 168
  start-page: 186
  year: 2013
  end-page: 191
  article-title: Weather conditions and daylight‐mediated photodynamic therapy: protoporphyrin IX‐weighted daylight doses measured in six geographical locations
  publication-title: Br J Dermatol
– volume: 29
  start-page: 1926
  year: 2015
  end-page: 1932
  article-title: Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra‐patient, prospective, comparison study in Italy
  publication-title: J Eur Acad Dermatol Venereol
– volume: 27
  start-page: 89
  year: 2017
  end-page: 91
  article-title: Long‐term efficacy and safety of daylight photodynamic therapy with methyl amninolevulinate for actinic keratosis of the face and scalp
  publication-title: Eur J Dermatol
– ident: e_1_2_5_4_1
  doi: 10.1111/jdv.13228
– ident: e_1_2_5_9_1
  doi: 10.1016/j.ijsu.2011.09.004
– ident: e_1_2_5_15_1
  doi: 10.1111/jdv.14613
– volume: 151
  start-page: 154
  year: 2014
  ident: e_1_2_5_12_1
  article-title: Daylight photodynamic therapy with methyl aminolaevulinate in patients with actinic keratoses: a preliminary experience in southern Italy
  publication-title: G Ital Dermatol Venereol
– ident: e_1_2_5_17_1
  doi: 10.1159/000366548
– ident: e_1_2_5_8_1
  doi: 10.1117/1.JBO.20.5.058001
– ident: e_1_2_5_7_1
  doi: 10.1159/000353775
– ident: e_1_2_5_11_1
  doi: 10.1111/j.1365-2133.2011.10209.x
– ident: e_1_2_5_5_1
  doi: 10.1111/j.1365-2133.2012.11200.x
– ident: e_1_2_5_16_1
  doi: 10.2340/00015555-2345
– ident: e_1_2_5_10_1
  doi: 10.1111/j.1600-0781.2011.00611.x
– ident: e_1_2_5_2_1
  doi: 10.1111/j.1365-2133.2008.08450.x
– ident: e_1_2_5_3_1
  doi: 10.1111/bjd.13138
– ident: e_1_2_5_6_1
  doi: 10.1111/jdv.12974
– ident: e_1_2_5_13_1
  doi: 10.1684/ejd.2016.2882
– ident: e_1_2_5_14_1
  doi: 10.1111/jdv.13076
SSID ssj0001158
Score 2.359864
Snippet Background We know the efficacy of daylight phototherapy dynamic (DL‐PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared...
We know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1730
SubjectTerms Aminolevulinic Acid - therapeutic use
Humans
Keratosis, Actinic - drug therapy
Light
Ointments - therapeutic use
Photochemotherapy
Photosensitizing Agents - therapeutic use
Scalp Dermatoses - drug therapy
Treatment Outcome
Title Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra‐individual study
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjdv.16208
https://www.ncbi.nlm.nih.gov/pubmed/31955461
https://www.proquest.com/docview/2342362105
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtUwELWqLio2vB_lpQGxYJOrXCdOYrpClKqqBAtEURdIkZ8iappUzb1Xald8Ah_YVb-EGedBy0uInaM4TqLMjM84Z44ZezHXhTSYF0SWexmlIk4jmfs80laKXM2VFiaofb7PdvfTvQNxsMa2xlqYXh9iWnAjzwjxmhxc6e6yk9vVbJ7xUOhLXC0CRB9-SEch0glRWPIsIk2tQVUosHjGK6_ORb8AzKt4NUw4OzfY5_FRe57J4Wy50DNz9pOK43--y012fQCi8Lq3nFtszTW32ca74Vf7HXa-jbk8Ze5w_KVdtLbfuR76eq1ToPVboO2nT2vAE01buxWR2hG6AgHRI6g6UB30fBEMqXRwmeL-l2F1vXTQ37tq6BRMdHhoPVApRoPXHJIedNtV3StQMFDua2cBZ1_bHlVn2Kxo6fri67dqKjuDoKd7l-3vvP34ZjcatoKITMJFEXluY2XQdKRL41QJlUmN2DbNJem1xZkqvJfci9xhBJIm81bYApFLnieJEblO7rH1pm3cAwY8czKzOBF4y1Ptc2UxBGHbFok2sRGb7OVoFKUZdNJpu466nPIluyrD19pkz6eux704yO86PRstq0TXpf8xqnHtsis5qS9mmHPjPe_3JjcNg5GR-INzfJpgOH8ev9zb_hQaD_-96yN2jdO6QSAyPmbri5Ole4LgaqGfBi_6DnIqJ4s
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIgEX3pTyNIgDl6yyTpzEiAuiVEtpe0At6gVFfoqoaVKR3ZXaEz-BH8iJX8KMnYSWlxA3R3GcRJkZz0y--YaQp1NVCA1xQWSYE1HK4zQSucsjZQTP5VQqrj3b524220-3DvjBCnkx1MIEfogx4Yaa4e01KjgmpM9quVlOphnDSt8L2NHbB1TvfpBHga_j7bBgWYSsWj2vkMfxDJee341-cTHPe6x-y9m8Sj4MDxuQJoeTxVxN9OlPPI7_-zbXyJXeF6Uvg_BcJyu2uUEu7vR_22-SrxsQzmPwTo8_tvPWhOb1NJRsnVBM4VLsQH1SUzjRtLVdIq4dvFeKvugRrToqOxogI2BV8eAsyv0vy6p6YWm4d9XgKToi4mnrKFZjNHDNIVJCt13VPaeS9qj72hoKG7Bpj6pTGFaYvf72-Us1Vp5RT6l7i-xvvt57NYv6bhCRThgvIsdMLDVIj7BpnEouM6HAvU1zgZRtcSYL5wRzPLdghITOnOGmAOclz5NE81wlt8lq0zb2DqEssyIzsBc4w1LlcmnACsHYFInSsebr5NkgFaXuqdKxY0ddjiGTWZb-a62TJ-PU48AP8rtJjwfRKkF78ZeMbGy76EqGBIwZhN1wz7Ugc-MyYBwRQjiFp_GS8-f1y62N935w99-nPiKXZns72-X2m92398hlhmkEj2u8T1bnnxb2Afhac_XQq9R3swMrpg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtUwELWqIlVseENbXgaxYJOrXCd2YlghLlelQIUQRV0gRX6KqGly1fuQ2hWfwAey4kuYcR60vITYOYrjJMrM-Ixz5piQR2OdSwN5QWSZl1HK4zSSmc8ibSXP1FhpboLa557Y2U93D_jBGnna18K0-hDDght6RojX6OAz6886uV2NxoJhoe-FVMQ5mvTk3Q_tKIA6IQxLJiIU1epkhQKNp7_0_GT0C8I8D1jDjDO9TD72z9oSTQ5Hy4UemdOfZBz_82WukEsdEqXPWtO5StZcfY1svOn-tV8nXyeQzGPqTmefmkVj263raVuwdUJxAZfi_tMnFYUTdVO5FbLaAbtSRKJHtJxTNactYQRiKh6c5bj_ZVhdLR1t713WeIoOfHjaeIq1GDVcc4iC0M28nD-hinac-8pZCtOvbY7KU2iWuHb97fOXcqg7o0FQ9wbZn754_3wn6vaCiEzCeB55ZmNlwHakS-NUcSWkBnCbZhIF22Khcu8l8zxzEIKkEd5ymwN0ybIkMTzTyU2yXje12ySUCSeFhZnAW5ZqnykLMQjaNk-0iQ3fIo97oyhMJ5SO-3VUxZAw2VURvtYWeTh0nbXqIL_r9KC3rAJ8F3_IqNo1y3nBUH5RQNIN97zVmtwwDIRGJBCO4WmC4fx5_GJ38iE0tv-9632y8XYyLV6_3Ht1m1xkuIYQSI13yPrieOnuAtBa6HvBob4DREMqXg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Daylight+photodynamic+therapy+with+methyl+aminolevulinate+cream+is+as+effective+as+conventional+photodynamic+therapy+with+blue+light+in+the+treatment+of+actinic+keratosis%3A+a+controlled+randomized+intra-individual+study&rft.jtitle=Journal+of+the+European+Academy+of+Dermatology+and+Venereology&rft.au=Assikar%2C+S&rft.au=Labrunie%2C+A&rft.au=Kerob%2C+D&rft.au=Couraud%2C+A&rft.date=2020-08-01&rft.issn=1468-3083&rft.eissn=1468-3083&rft.volume=34&rft.issue=8&rft.spage=1730&rft_id=info:doi/10.1111%2Fjdv.16208&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0926-9959&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0926-9959&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0926-9959&client=summon